One of the most common conversations in PE operating partner discussions is this. The fund has 20 or 25 portfolio companies. Each one has its own commercial situation, its own commercial team, its own set of issues. When commercial performance starts to slip on a PortCo, the operating partner brings in a diagnostic. It might be the firm’s own value creation team. It might be an external adviser. It might be a new CRO with their own methodology. Whoever it is, the diagnostic is run bespoke for that PortCo, in the context of that PortCo, with its own metrics and its own definition of what good looks like.
The work gets done, often well. But it gets done in isolation. The next PortCo that hits a commercial wobble six months later gets a different diagnostic, run by a different person, against different metrics. The fund has 25 individual commercial interventions running in parallel, with very little portfolio-level commercial capability beneath them.
That model has worked for a long time. It is starting to break, and the data shows the firms that have built portfolio-level commercial methodology are pulling ahead measurably.
McKinsey’s research shows that the share of PE firms applying a consistent value-creation model across their portfolios has increased from roughly 50% to 75% over the past decade. That trend has been quiet but consistent, pointing to where the industry is heading. Portfolio-level commercial discipline has shifted from being a differentiator to being an expectation.
The pressure is coming from two directions.
The first is LPs. 53 percent of 300 LPs surveyed in January 2026 ranked a GP’s value creation strategy a top-five metric when selecting a manager. That placed it third on the criteria list, behind only performance and quality of the investment team and diligence. It has replaced sectoral expertise as the third-most-important metric when the same LPs were surveyed a year earlier. The shift in what LPs are scoring matters. GPs that cannot demonstrate a consistent, repeatable, portfolio-level approach to creating value post-investment are now at a structural disadvantage in fundraising.
The second is operational. McKinsey research on PE operating groups shows portfolio operations teams now spend 49% of their time driving measurable performance improvements, compared to just 19% on monitoring. The role of the operating partner has shifted from oversight to active commercial intervention. That shift only scales if there is a consistent methodology underneath it. Without one, the operating partner is the bottleneck.
And the underlying value creation math has not changed. McKinsey’s analysis of more than 100 PE funds with vintages after 2020 found that GPs that focus on operational value creation achieve internal rates of return up to 2-3 percentage points higher than peers. Over a typical hold period and at fund scale, that is the difference between the top quartile and the median performance.
Three costs are visible in the funds we have worked with.
Inconsistent diagnostic quality. When every PortCo receives a different commercial diagnostic from a different adviser or operating partner, the depth and rigour vary significantly. Some get a forensic review of processes, infrastructure, and capabilities. Others get a high-level strategy refresh dressed up as a diagnostic. The fund has no portfolio-level visibility into which PortCos are well-diagnosed and which are not, until performance eventually reveals it.
No learning transfer. When the diagnostic for PortCo A is run independently of the diagnostic for PortCo B, the insights that emerge from one rarely make it to the other. If a sales process intervention worked particularly well at one PortCo, that knowledge stays inside that PortCo. The fund spends 25 times to learn the same thing 25 times, instead of learning it once and applying it 25 times.
Operating partner capacity does not scale. The bespoke model relies on the operating partner being personally close to each PortCo’s commercial situation. With 20 plus PortCos in a typical fund, that personal closeness becomes unsustainable. The operating partner ends up firefighting whichever PortCo is in the loudest trouble that month, while the quieter ones drift unnoticed. The bespoke model rewards reactivity and punishes prevention.
The funds that have shifted to a portfolio-level commercial methodology have eliminated these costs without losing the bespoke depth where it matters.
The methodology is consistent. The application is contextual.
In our work with PE-backed businesses, the funds that have built genuine portfolio-level capability have three things in common.
A consistent diagnostic applied to every PortCo at investment. Not a bespoke piece of work designed from scratch each time. A standardised commercial diagnostic that captures process maturity, infrastructure readiness, capability gaps, and forward fit against the investment thesis. The diagnostic is the same across PortCos, so the fund can benchmark and compare. The findings are bespoke to the PortCo, because every business is different.
A shared commercial methodology across the portfolio. Not Challenger here, MEDDIC there, and an in-house framework somewhere else. A single methodology that every PortCo applies, calibrated to its specific sector and sales motion. Sellers move between PortCos with a shared language. Operating partners can compare commercial performance against a consistent benchmark. The portfolio operating group can build genuine commercial pattern recognition.
Learning that transfers from PortCo to PortCo deliberately, not accidentally. A structured way of capturing what is working in one PortCo and applying it in another. Quarterly portfolio reviews focused on commercial performance, with cross-PortCo insight sharing built in. A central repository of plays that have worked. A way of identifying when one PortCo’s commercial breakthrough is replicable across others in the portfolio.
These three things turn the fund from a holding company managing 25 commercial transformations into a commercial operating system that runs across 25 businesses. The difference is significant in both returns and how the fund presents to LPs.
The portfolio-level argument lands in two specific places that PE firms care about.
The first is fundraising. As LP appetite has shifted toward GPs that can demonstrate consistent value-creation capability, firms that can show a real portfolio-level methodology have a meaningful fundraising advantage. The pitch has shifted from “we are good at picking companies” to “we are good at improving the ones we pick.” The funds that have invested in portfolio-level commercial capability can tell that story credibly. The funds that have not, cannot.
The second is exit valuation. Across Europe over the past six years, assets growing at more than 25 per cent CAGR have sold at roughly a 50 per cent premium relative to assets growing at less than 5 per cent. Commercial growth at exit is no longer a soft factor in valuation. It is the dominant factor, and the buyers running CDD on the asset will dig into how the growth was generated. PortCos that can demonstrate institutional-grade commercial methodology rather than founder-led commercial heroics command the premium.
A 2022 survey of general partners found 94 per cent believe PortCo leadership contributes an average of 53 per cent toward investment returns. The capability of commercial leadership within the PortCo, in GPs’ own assessment, accounts for more than half of the return. Building that capability portfolio-wide rather than one PortCo at a time is the leverage point.
The PE firms that move first on this will keep compounding the advantage. Portfolio-level commercial capability is remains scarce in the market right now, and LPs are pricing it. The funds that have built it are gaining ground in fundraising, in operating leverage, and in exit valuation. The funds that have not are increasingly being asked harder questions by their LPs about how they actually create value, and finding it harder to answer them.
For PortCo leadership teams, the same shift is worth understanding. The next time a fund acquires your business, or you join a PE-backed PortCo, the commercial diagnostic you experience is increasingly likely to be applied against a portfolio-level methodology rather than designed from scratch for your business. That is generally good news. It means the fund has invested in capability, and your business benefits from pattern recognition built across the portfolio.
The work needed to make this shift is significant, but the case for it is now clear. The data shows where the returns are going. The LPs have repriced their expectations. The operating partner model is restructuring around it. The funds that have built portfolio-level commercial methodology are pulling ahead. The funds that have not, are quietly falling behind.
If you would like to talk through how your fund’s commercial methodology is structured across the portfolio, get in touch with the Sales Engine team.
John Toal is Account Director at Sales Engine.
New to Sales Engine? Begin with the Commercial Performance Diagnostic.
